Skip to main content

Vyndamax for Transthyretin-Related Amyloidosis User Reviews

Rating: 8.7

Vyndamax has an average rating of 8.7 out of 10 from a total of 3 reviews for the treatment of transthyretin-related amyloidosis. 67% of reviewers reported a positive experience, while 0% reported a negative experience.

10
33%
9
33%
8
0%
7
33%
6
0%
5
0%
4
0%
3
0%
2
0%
1
0%
  • Ton...
  • Taken for 1 to 6 months
  • August 2, 2024

"I started taking Vyndamax in January 2024. Since then I have been experiencing a blood blister on my tongue about once a month. Then about three weeks ago, along with the blood blister my tongue went black with a fungus, which my cardiologist noted and reported to my GP. I presume Vyndamax has been reasonably effective in stopping the progress of my amyloidosis."

7 / 10
Was this helpful?YesNo
3 Report
  • hoo...
  • Taken for 1 to 2 years
  • April 17, 2025

"15 months taking Vyndamax. I have never had side effects. My doctor and I have no way of knowing if Vyndamax is doing anything. No way to measure or compare against other patients. I feel good and I hope that I am 'buying' some time."

9 / 10
Was this helpful?YesNo
0 Report
  • Sam...
  • Taken for 1 to 2 years
  • December 16, 2023

"My husband has been taking this drug for 1 year. It is working very well for him. His heart is stable right now. We saw improvements within 2 months. It has been a lifesaver."

10 / 10
Was this helpful?YesNo
7 Report

Frequently asked questions

Are you taking this medicine?

Your review helps others make informed decisions.
Write a review
Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.

Learn more about Transthyretin-Related Amyloidosis

Care guides